1. 38 studies 89 arms 3923 patients ▪ lack of control group unless
Potentially relevant CTs identified
and screened for retrieval (N=115)
RCTs included in the analysis
Short term CTs: duration ≤12 weeks (N=38)
Potentially appropriate RCTs to be
Included in the analysis (N=64)
RCTs excluded because of:
▪ design (crossover, combination,
retrospective, discontinuation) (N=8)
▪ lack of control group unless
duration ≥ 13 weeks (N=26)
▪ other interests (young adults,
pharmaco/vigilance or kinetics (N=9)
▪ Review or meta-analysis (N=6)
▪ Arm with N < 9 (N=2)
RCTs excluded from analysis because
of data reported elsewhere (N=9)
Long term CTs: duration ≥13 weeks (N=16)
38 studies
89 arms
3923 patients
Incomplete reporting of all variables of interest (N=1)

2. Weight gain : compared to placebo
29 studies
65 arms patients
Weight gain : compared to placebo kg
Arm (N)
Patient (N) 4
228 61 8
606 7
413 10
351 16
691 16
854
Placebo

3. Patients with significant weight gain
24 studies
57 arms patients
Patients with significant weight gain
Arm (N)
Patient (N) 3
212 57 8
612 5
345
297 15
759 15
947
Placebo

4. 12 studies
32 arms patients
Arm (N)
Patient (N) 1 12 8
606 3 68
324 5
131 7
370
Placebo

5. 10 studies
27 arms patients
mg/dl
Arm (N)
Patient (N) 3
212
243 5
371 4
259
187 8
512
Placebo

6. 10 studies
27 arms patients
mg/dl
Arm (N)
Patient (N) 3
212
243 5
371 4
259
187 8
512
Placebo

7. 10 studies
27 arms patients
mg/dl
Arm (N)
Patient (N) 3
212
243 6
388
152 4
187 8
473
Placebo

8. somnolence/sedation : compared to placebo
29 studies
64 arms patients
somnolence/sedation : compared to placebo
Arm (N)
Patient (N) 7
228 1 12 8
612
404
254 17
775 19
1020
Placebo

9. 26 studies
61 arms patients
Arm (N)
Patient (N) 3
212 8
612 6
362
109 21
938 17
976
Placebo

10. Risperidone Olanzapine Quetiapine Aripiprazole Clozapine Ziprasidone
 Weight ++
++++
+++ +
 Glucose
+/- ?
 Cholesterol
 Trigly
 Prolactin
Somnolence
Extra-pyramidal 0?